214 related articles for article (PubMed ID: 24916745)
1. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Combs SE; Habermehl D; Kessel KA; Bergmann F; Werner J; Naumann P; Jäger D; Büchler MW; Debus J
Ann Surg Oncol; 2014 Aug; 21(8):2801-7. PubMed ID: 24916745
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
Sherman WH; Hecht E; Leung D; Chu K
Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Habermehl D; Kessel K; Welzel T; Hof H; Abdollahi A; Bergmann F; Rieken S; Weitz J; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
Radiat Oncol; 2012 Mar; 7():28. PubMed ID: 22385572
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
7. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
[TBL] [Abstract][Full Text] [Related]
8. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
[TBL] [Abstract][Full Text] [Related]
9. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.
Chao YJ; Sy ED; Hsu HP; Shan YS
BMC Surg; 2014 Sep; 14():72. PubMed ID: 25258022
[TBL] [Abstract][Full Text] [Related]
10. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Nanda RH; El-Rayes B; Maithel SK; Landry J
J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
[TBL] [Abstract][Full Text] [Related]
13. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
15. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
[TBL] [Abstract][Full Text] [Related]
16. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
[TBL] [Abstract][Full Text] [Related]
19. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Golden DW; Novak CJ; Minsky BD; Liauw SL
Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Yang PC; Huang KW; Pua U; Kim MD; Li SP; Li XY; Liang PC
Eur J Surg Oncol; 2020 May; 46(5):811-817. PubMed ID: 31839436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
